Kraig Biocraft Laboratories Inc (KBLB)

[DimesForShares]

Precisely why we can’t uplist.

Thank you Hope for sharing the regulations that show why KBLB is nowhere close to uplisting. As your post made it clear, all three paths require at least $4 million in equity. Currently KBLB has negative equity of perhaps $4 to $5 million, meaning the company will need at least $8 million to get us to where we need to be.

This equity cannot come from a loan of any kind, as loans decrease equity (since the loan must be repaid with interest).

Thompson perhaps has a potential exclusive licensing agreement that might provide a boost to our equity, but with projected sales of $2.4 million in 2020, it seems unlikely that a company would invest more than a million or so to be able to buy all $2.4 million of our product next year. That would be bad business indeed.